1380422-46-7

Upstream product

• 942153-03-9 (R)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)morpholine-3-carboxylic acid 
• 71989-14-5 N-(9-fluorenylmethoxycarbonyl)-4-O-tert-butyl-D-aspartic acid 
• 118488-18-9 Fmoc-D-Tyr(O-tBu)-OH 
• 187618-60-6 Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 

Downstream Products

• 1402162-75-7 C₄₇H₆₈N₈O₁₂S 
• 1402162-87-1 C₂₆H₃₆N₈O₉ 
• 1380422-43-4 C₂₆H₃₅IN₈O₉ 

Relevant academic research and scientific papers

125I-radiolabeled morpholine-containing arginine-glycine- aspartate (RGD) ligand of αvβ3 integrin as a molecular imaging probe for angiogenesis

In this paper, using a hybrid small-animal Micro SPECT/CT imaging system, we report that a new 125I-Cilengitide-like RGD-cyclopentapeptide, containing d-morpholine-3-carboxylic acid, interacts in vivo with αvβ3 integrin expressed by melanoma cells. Images clearly show that the 125I-compound has the capacity to monitor the growth of a melanoma xenograft. Indeed, retention of the labeled ligand in the tumor mass has a good tumor/background ratio, and a significant reduction of its uptake was observed after injection of unlabeled ligand. These results suggest that the use of 125I-labeled morpholine-based RGD-cyclopentapeptides targeting αvβ3 positive tumors may play a role in future therapeutic strategies.